1
|
Kim Y, Park J, Kim B, Yu K, Kim HS, Oh Y, Seo K, Ryu M, Park C, Bhang D, Choi U, Youn H. Serum thymidine kinase 1 protein concentrations and presence of its autoantibody as biomarkers for screening dogs with malignant tumors. J Vet Intern Med 2024; 38:300-307. [PMID: 38088206 PMCID: PMC10800180 DOI: 10.1111/jvim.16946] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2022] [Accepted: 11/10/2023] [Indexed: 01/23/2024] Open
Abstract
BACKGROUND An accurate and easily accessible method for diagnosing malignancies in local veterinary clinics has not yet been established. OBJECTIVES To investigate the usefulness of serum thymidine kinase 1 (TK1) protein and its autoantibody as tumor biomarkers in dogs. ANIMALS Serum samples from 1702 dogs were collected from local animal hospitals and referral animal medical centers in South Korea. METHODS TK1 protein OD value and TK1 autoantibody ratio (TK1 autoantibody OD/total IgG OD) in serum samples of dogs classified into healthy controls, group with nontumor disease, group with benign and group with malignant tumors were measured using lateral flow immunochromatographic assay methods. RESULTS TK1 autoantibody levels were significantly higher in malignant tumor group (median 0.71) than in healthy controls (median 0.34), group with nontumor disease (median 0.34), and group with benign tumor (median 0.32, Welch t test, P < .0001). They were also significantly different among dogs with carcinomas (median 0.77), hematopoietic tumors (median 0.71), and sarcomas (median 0.56) than in healthy controls (median 0.34, post hoc Games-Howell test, P < .0001). In the receiver operating characteristic curve of TK1 protein, AUC was 0.633 (95% CI: 0.592-0.675, P < .0001). The AUC of TK1 autoantibody ratio was 0.758 (95% CI: 0.723-0.793, P < .0001). CONCLUSIONS AND CLINICAL IMPORTANCE TK1 autoantibody is a potentially useful biomarker for differentiating between healthy and tumor-bearing dogs, better than TK1 protein measurement. However, both were inadequate when used as single biomarkers for screening dogs to discover occult malignant tumors.
Collapse
Affiliation(s)
- Yoonhee Kim
- College of Veterinary MedicineJeonbuk National University, 79 Gobong‐roIksan‐siJeollabuk‐doSouth Korea
| | - Jeongjoo Park
- Biattic Inc., #305, 16 Heungan‐daero, Dongan‐guAnyang‐siGyeonggi‐doSouth Korea
| | - Byunggak Kim
- Biattic Inc., #305, 16 Heungan‐daero, Dongan‐guAnyang‐siGyeonggi‐doSouth Korea
| | - Kyung‐Rok Yu
- Department of Agricultural Biotechnology and Research Institute of Agriculture and Life SciencesSeoul National University, 1 Gwanak‐ro, Gwanak‐guSeoulSouth Korea
| | - Hong Sook Kim
- Department of Biological SciencesSungkyunkwan University, 2066 Seobu‐ro, Jangan‐guSuwonGyeonggi‐doSouth Korea
| | - Yein Oh
- College of Veterinary MedicineKyungpook National University, 80 Daehak‐ro, Buk‐guDaeguSouth Korea
| | - Kyoungwon Seo
- College of Veterinary MedicineSeoul National University, 1 Gwanak‐ro, Gwanak‐guSeoulSouth Korea
| | - Minok Ryu
- College of Veterinary MedicineSeoul National University, 1 Gwanak‐ro, Gwanak‐guSeoulSouth Korea
| | - Chul Park
- College of Veterinary MedicineJeonbuk National University, 79 Gobong‐roIksan‐siJeollabuk‐doSouth Korea
| | - Dongha Bhang
- Biattic Inc., #305, 16 Heungan‐daero, Dongan‐guAnyang‐siGyeonggi‐doSouth Korea
| | - Ulsoo Choi
- College of Veterinary MedicineJeonbuk National University, 79 Gobong‐roIksan‐siJeollabuk‐doSouth Korea
| | - Hwayoung Youn
- College of Veterinary MedicineSeoul National University, 1 Gwanak‐ro, Gwanak‐guSeoulSouth Korea
| |
Collapse
|
2
|
Sharif H, Saellström S, Kolli B, Jagarlamudi KK, Wang L, Rönnberg H, Eriksson S. A monoclonal antibody-based sandwich ELISA for measuring canine Thymidine kinase 1 protein and its role as biomarker in canine lymphoma. Front Vet Sci 2023; 10:1243853. [PMID: 37808109 PMCID: PMC10557065 DOI: 10.3389/fvets.2023.1243853] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2023] [Accepted: 08/25/2023] [Indexed: 10/10/2023] Open
Abstract
Introduction Dogs play an important role in society, which increased during the covid epidemics. This has led to a much higher workload for the veterinarians. Therefore, there is a need for efficient diagnostic tools to identify risk of malignant diseases. Here the development of a new test that can solve some of these problems is presented. It is based on serum Thymidine Kinase 1 (TK1), which is a biomarker for cell proliferation and cell lysis. Methods Anti-TK1 monoclonal antibodies were produced against two different epitopes, the active site of the TK1 protein and the C-terminal region of canine TK1. The antibodies were developed with hybridoma technology and validated using dot blot, Quartz Crystal Microbalance (QCM) technology, western blots, immunoprecipitation (IP), and enzyme-linked immunosorbent assay (ELISA). Clinical evaluation of Canine TK1 ELISA was done by using sera from 131 healthy dogs and 93 dogs with lymphoma. The two selected Anti-TK1 monoclonal antibodies have Kd values in the range of 10-9 M and further analysis with dot and western blots confirmed the high affinity binding of these antibodies. A sandwich Canine TK1 ELISA was developed using the anti-TK1 antibodies, and TK1 concentrations in serum samples were determined using dog recombinant TK1 as a standard. Results Serum TK1 protein levels were significantly higher in dogs with lymphoma compared to those in healthy dogs (p < 0.0001). Receiver operating curve analysis showed that the canine TK1-ELISA obtain a sensitivity of 0.80, at a specificity of 0.95. Moreover, the Canine TK1 ELISA has a positive predictive value (PPV) of 97%, and the negative predictive value (NPV) of 83%, reflecting the proportion of test results that are truly positive and negative. Furthermore, Canine TK1 ELISA had significantly higher capacity to differentiate dogs with T-cell lymphoma from those with B-cell lymphoma compared to earlier used TK1 activity assays. Discussion These results demonstrate that the Canine TK1 ELISA can serve as an efficient tool in the diagnosis and management of dogs with lymphomas.
Collapse
Affiliation(s)
- Hanan Sharif
- Alertix Veterinary Diagnostics AB, Stockholm, Sweden
- Department of Anatomy, Physiology, and Biochemistry, Swedish University of Agricultural Sciences, Biomedical Center, Uppsala, Sweden
| | - Sara Saellström
- University Animal Hospital, Swedish University of Agricultural Sciences, Uppsala, Sweden
| | - Bhavya Kolli
- Alertix Veterinary Diagnostics AB, Stockholm, Sweden
| | | | - Liya Wang
- Department of Anatomy, Physiology, and Biochemistry, Swedish University of Agricultural Sciences, Biomedical Center, Uppsala, Sweden
| | - Henrik Rönnberg
- University Animal Hospital, Swedish University of Agricultural Sciences, Uppsala, Sweden
- Center of Clinical Comparative Oncology (C3O), Department of Clinical Sciences, Swedish University of Agricultural Sciences, Uppsala, Sweden
| | - Staffan Eriksson
- Alertix Veterinary Diagnostics AB, Stockholm, Sweden
- Department of Anatomy, Physiology, and Biochemistry, Swedish University of Agricultural Sciences, Biomedical Center, Uppsala, Sweden
| |
Collapse
|
3
|
Zaidi B, Mukhopadhyay A, Ramos-Vara JA, Dhawan D, Ruple A, Childress MO. Serum thymidine kinase 1 activity as a prognostic biomarker in dogs with chemotherapy-treated diffuse large B-cell lymphoma. Vet Comp Oncol 2023; 21:200-207. [PMID: 36651594 DOI: 10.1111/vco.12876] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2022] [Revised: 11/02/2022] [Accepted: 12/29/2022] [Indexed: 01/19/2023]
Abstract
Diffuse large B-cell lymphoma (DLBCL) is frequently treated with chemotherapy incorporating cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP), which induces remission in 80% to 95% of cases. However, not all dogs derive meaningful benefit from CHOP, and prognostic factors for dogs with DLBCL are poorly defined. Serum thymidine kinase 1 (TK1) activity, a marker of tumour cell proliferation, has shown promising initial results as a prognostic biomarker in dogs with multicentric lymphomas. The purpose of this study was to determine if baseline serum TK1 activity is associated with clinical outcome in dogs with CHOP-treated DLBCL. Baseline serum TK1 activity was measured in banked sera from 98 dogs with CHOP-treated DLBCL using a commercially available ELISA kit. Data on other potential prognostic factors were abstracted retrospectively from electronic medical records. Multivariable statistical methods were used to identify associations between TK1 and other potential prognostic factors with progression-free survival (PFS) and attainment of complete remission. TK1 activity at baseline was not associated with PFS (p = .299) or attainment of complete remission (p = .910) following CHOP chemotherapy. Of the other prognostic factors analysed, only purebred (vs. mixed breed) status (HR 8.81, 95% CI 1.68-46.30, p = .010), attainment of complete (vs. partial) remission (HR 0.09, 95% CI 0.02-0.49, p = .006), and baseline serum C-reactive protein concentration (HR 1.19, 95% CI 1.07-1.32, p = .001) were independently associated with PFS. Based on these findings, baseline serum TK1 activity does not appear to be a useful prognostic biomarker in dogs with CHOP-treated DLBCL.
Collapse
Affiliation(s)
- Bushra Zaidi
- Department of Veterinary Clinical Sciences, College of Veterinary Medicine, Purdue University, West Lafayette, Indiana, USA
| | - Abhijit Mukhopadhyay
- Department of Veterinary Clinical Sciences, College of Veterinary Medicine, Purdue University, West Lafayette, Indiana, USA
| | - José A Ramos-Vara
- Department of Comparative Pathobiology, College of Veterinary, Purdue University, West Lafayette, Indiana, USA
| | - Deepika Dhawan
- Department of Veterinary Clinical Sciences, College of Veterinary Medicine, Purdue University, West Lafayette, Indiana, USA
| | - Audrey Ruple
- Department of Comparative Pathobiology, College of Veterinary, Purdue University, West Lafayette, Indiana, USA
| | - Michael O Childress
- Department of Veterinary Clinical Sciences, College of Veterinary Medicine, Purdue University, West Lafayette, Indiana, USA
| |
Collapse
|
4
|
Pinheiro BQ, de Magalhães FF, Alves FWDS, Silva ING, Faustino AMR, da Silva LDM. CA 15-3, CRP, and LDH correlates with prognostic parameters in canine mammary neoplasms. Anim Reprod 2023; 20:e20220086. [PMID: 36938312 PMCID: PMC10023068 DOI: 10.1590/1984-3143-ar2022-0086] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2022] [Accepted: 02/01/2023] [Indexed: 03/15/2023] Open
Abstract
The identification of putative prognostic factors in canine mammary neoplasms (CMNs) has been focused on tissue-specific biomarkers, but the serum biomarkers, including cancer antigen 15-3 (CA 15-3), c-reactive protein (CRP), and lactate dehydrogenase (LDH) have been demonstrated to display clinical application in cases of CMNs. The aim of the study was to evaluate the levels of these serum biomarkers and their association with well-established prognostic factors in CMNs. Samples from 15 female canines with CMNs and 15 clinically healthy ones were collected. The results were evaluated using the Tukey's, Pearson, or Spearman tests. The cut-off point, sensitivity, specificity, and area under curve (AUC) were evaluated using the receiver operating characteristic (ROC) curve analysis in a logistic regression model (P<0.05). The levels of CA 15-3, CRP and LDH were significantly higher in the serum of female dogs with CMNs compared to the healthy ones. Moreover, these factors were positively correlated with ulceration, tumor size, histopathological grade, metastatic lymph node, and clinical staging. Female dogs with CMNs were found to exhibit highest serum levels of CA 15-3, CRP, and LDH. Therefore, they can be applied to improve the efficacy of the diagnosis and prognostic evaluation in casas of CMNs.
Collapse
Affiliation(s)
- Breno Queiroz Pinheiro
- Laboratório de Reprodução de Carnívoros, Faculdade de Veterinária, Universidade Estadual do Ceará, Fortaleza, CE, Brasil
| | - Francisco Felipe de Magalhães
- Laboratório de Reprodução de Carnívoros, Faculdade de Veterinária, Universidade Estadual do Ceará, Fortaleza, CE, Brasil
| | - Francisco Wesley da Silva Alves
- Laboratório de Patologia Clínica Veterinária, Faculdade de Veterinária, Universidade Estadual do Ceará, Fortaleza, CE, Brasil
| | - Isaac Neto Goes Silva
- Laboratório de Patologia Clínica Veterinária, Faculdade de Veterinária, Universidade Estadual do Ceará, Fortaleza, CE, Brasil
| | - Augusto Manuel Rodrigues Faustino
- Departamento de Patologia e Imunologia Molecular, Instituto de Ciências Biomédicas de Abel Salazar, Universidade do Porto, Porto, Portugal
| | - Lúcia Daniel Machado da Silva
- Laboratório de Reprodução de Carnívoros, Faculdade de Veterinária, Universidade Estadual do Ceará, Fortaleza, CE, Brasil
- Corresponding author:
| |
Collapse
|
5
|
Manachai N, Umnuayyonvaree D, Punyathi P, Rungsipipat A, Rattanapinyopituk K. Impact of serum C-reactive protein level as a biomarker of cancer dissemination in canine lymphoid neoplasia. Vet World 2022; 15:2810-2815. [PMID: 36718344 PMCID: PMC9880848 DOI: 10.14202/vetworld.2022.2810-2815] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2022] [Accepted: 10/26/2022] [Indexed: 12/14/2022] Open
Abstract
Background and Aim C-reactive protein (CRP) is a highly sensitive but non-specific acute phase protein that has been widely used to predict the biological behavior of patients with cancer. This study aimed to examine the significance of the serum CRP biomarker in predicting the prognosis of dogs with lymphoma. Materials and Methods Blood samples (5 mL) were collected from 34 lymphoma dogs and control healthy dogs. Canine lymphoma clinical staging was classified using the World Health Organization (WHO) criteria. All lymphoma dogs were reclassified into two groups based on the disease stage. Stages IV and V were designated as advanced stages, and Stages I-III were designated as other stages. The serum CRP level was then determined using a commercial canine CRP fluorescent immunoassay kit and routine hematological and biochemical analyses. C-reactive protein levels, circulating inflammatory parameters, such as neutrophil-to-lymphocyte ratio, lymphocyte-to-monocyte ratio, and platelet-to-lymphocyte ratio, and albumin levels were compared between advanced stages (IV and V) and Stages I to III using Mann-Whitney U tests. Receiver operating characteristic (ROC) curves were also generated to determine the cutoff value, diagnostic sensitivity, and specificity of the CRP level. Results A prospective study identified 34 dogs recently diagnosed with canine lymphoma. C-reactive protein levels were significantly higher in lymphoma dogs in advanced stages (IV and V) than in lymphoma dogs in Stages I-III. According to the ROC curve analysis, a CRP cutoff level of 54.1 mg/L indicates advanced-stage canine lymphoma, which can be used as a biomarker to predict cancer dissemination. Conclusion Serum CRP concentrations can assist clinical decision-making on the WHO stage in lymphoma dogs in clinical applications. The limitations of this study include a small number of lymphomas and no survival analysis.
Collapse
Affiliation(s)
- Nawin Manachai
- Department of Pathology, Faculty of Veterinary Science, Chulalongkorn University, Pathumwan, Bangkok, Thailand,Center of Excellence - Companion Animal Cancer (CE-CAC), Chulalongkorn University, Pathumwan, Bangkok, Thailand,Department of Companion Animals and Wildlife Clinics, Faculty of Veterinary Medicine, Chiang Mai University, Chiang Mai, Thailand
| | - Duangchanok Umnuayyonvaree
- Department of Pathology, Faculty of Veterinary Science, Chulalongkorn University, Pathumwan, Bangkok, Thailand,Center of Excellence - Companion Animal Cancer (CE-CAC), Chulalongkorn University, Pathumwan, Bangkok, Thailand
| | - Panitnan Punyathi
- Department of Pathology, Faculty of Veterinary Science, Chulalongkorn University, Pathumwan, Bangkok, Thailand,Center of Excellence - Companion Animal Cancer (CE-CAC), Chulalongkorn University, Pathumwan, Bangkok, Thailand
| | - Anudep Rungsipipat
- Department of Pathology, Faculty of Veterinary Science, Chulalongkorn University, Pathumwan, Bangkok, Thailand,Center of Excellence - Companion Animal Cancer (CE-CAC), Chulalongkorn University, Pathumwan, Bangkok, Thailand
| | - Kasem Rattanapinyopituk
- Department of Pathology, Faculty of Veterinary Science, Chulalongkorn University, Pathumwan, Bangkok, Thailand,Center of Excellence - Companion Animal Cancer (CE-CAC), Chulalongkorn University, Pathumwan, Bangkok, Thailand,Corresponding author: Kasem Rattanapinyopituk, e-mail: Co-authors: NM: , DU: , PP: , AR:
| |
Collapse
|
6
|
Colombe P, Béguin J, Benchekroun G, Le Roux D. Blood biomarkers for canine cancer, from human to veterinary oncology. Vet Comp Oncol 2022; 20:767-777. [PMID: 35815441 PMCID: PMC9796515 DOI: 10.1111/vco.12848] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2022] [Revised: 07/05/2022] [Accepted: 07/07/2022] [Indexed: 01/01/2023]
Abstract
In recent decades, interest in circulating tumour biomarkers is increasing both in human and veterinary oncology. An ideal tumour biomarker would allow early diagnosis of neoplasia, identify it specifically, accurately, establish a prognosis and predict its behaviour, especially regarding different therapeutic solutions. It would also allow to monitor its evolution over time and all this in a non-invasive and inexpensive way. Actually, no biomarkers meeting all of these criteria have been identified in veterinary medicine, particularly due to a lack of specificity of the main protein tumour biomarkers studied to date. However, great hope is currently placed in biomarkers grouped under the name of liquid biopsy, which could prove to be effective tools for common clinical use in the near future. This review gives an update on blood cancer biomarkers studied in dogs, such as ions, proteins, nucleic acids and also circulating cells, of which some might become more prominent in the coming years to help improve the management of animal care.
Collapse
Affiliation(s)
- Philippe Colombe
- Ecole Nationale Vétérinaire d'AlfortBioPôle AlfortMaisons‐AlfortFrance,Ecole Nationale Vétérinaire d'AlfortCHUVA, Service de Médecine InterneMaisons‐AlfortFrance
| | - Jérémy Béguin
- Ecole Nationale Vétérinaire d'AlfortCHUVA, Service de Médecine InterneMaisons‐AlfortFrance,Anses, INRAE, Ecole Nationale Vétérinaire d'AlfortUMR VIROLOGIE, Laboratoire de Santé AnimaleMaisons‐AlfortFrance
| | - Ghita Benchekroun
- Ecole Nationale Vétérinaire d'AlfortCHUVA, Service de Médecine InterneMaisons‐AlfortFrance,Ecole nationale Vétérinaire d'AlfortUniv Paris Est Créteil, INSERM, IMRBMaisons‐AlfortFrance
| | - Delphine Le Roux
- Ecole Nationale Vétérinaire d'AlfortBioPôle AlfortMaisons‐AlfortFrance,Anses, INRAE, Ecole Nationale Vétérinaire d'AlfortUMR BIPAR, Laboratoire de Santé AnimaleMaisons‐AlfortFrance
| |
Collapse
|
7
|
Saellström S, Sharif H, Jagarlamudi K, Rönnberg H, Wang L, Eriksson S. Serum TK1 protein and C-reactive protein correlate to treatment response and predict survival in dogs with hematologic malignancies. Res Vet Sci 2022; 145:213-221. [DOI: 10.1016/j.rvsc.2022.02.019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2021] [Revised: 01/13/2022] [Accepted: 02/18/2022] [Indexed: 10/19/2022]
|
8
|
Keany KM, Fosgate GT, Perry SM, Stroup ST, Steiner JM. Serum concentrations of canine pancreatic lipase immunoreactivity and C-reactive protein for monitoring disease progression in dogs with acute pancreatitis. J Vet Intern Med 2021; 35:2187-2195. [PMID: 34250650 PMCID: PMC8478023 DOI: 10.1111/jvim.16218] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2021] [Revised: 06/19/2021] [Accepted: 06/22/2021] [Indexed: 12/02/2022] Open
Abstract
Background Reliable biomarkers for monitoring disease progression and management in dogs with acute pancreatitis have not been described. Objective To determine if serum concentrations of canine pancreatic lipase immunoreactivity (cPLI) and C‐reactive protein (CRP) can be used as biomarkers for disease progression in hospitalized dogs with acute pancreatitis. Animals Thirteen hospitalized dogs with acute pancreatitis diagnosed based on clinical signs, serum cPLI concentrations, and imaging findings were enrolled. Methods Serum cPLI and CRP concentrations were determined before and then daily during hospital management and 1 week after hospital discharge. Modified canine activity index (MCAI) and canine acute pancreatitis clinical severity index (CAPCSI) scores were calculated daily for each patient while hospitalized. Results The MCAI scores (P = .03) but not CAPCSI scores (P = .31) were significantly different between dogs that survived to discharge (n = 11) and those that did not (n = 2). Serum cPLI concentration was positively correlated with MCAI (rho = 0.42; P = .01). Serum CRP concentration also was positively correlated with the MCAI (rho = 0.42, P = .01). Conclusions Serum cPLI and possibly CRP could be used as objective biomarkers for clinical changes in hospitalized dogs with acute pancreatitis. Additional studies involving larger numbers of dogs would be warranted to evaluate the broader impact of these findings.
Collapse
Affiliation(s)
- Kirstin M Keany
- MedVet New Orleans, Louisiana and MedVet Mandeville, Louisiana, USA
| | - Geoffrey T Fosgate
- Department of Production Animal Studies, Faculty of Veterinary Science, University of Pretoria, Onderstepoort, South Africa
| | - Sean M Perry
- Department of Veterinary Services, Mississippi Aquarium, Gulfport, Mississippi, USA
| | - Shannon T Stroup
- MedVet New Orleans, Louisiana and MedVet Mandeville, Louisiana, USA
| | - Joerg M Steiner
- Gastrointestinal Laboratory, Department of Small Animal Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Texas A&M University, College Station, Texas, USA
| |
Collapse
|
9
|
Wilson-Robles H, Miller T, Jarvis J, Terrell J, Kelly TK, Bygott T, Bougoussa M. Characterizing circulating nucleosomes in the plasma of dogs with hemangiosarcoma. BMC Vet Res 2021; 17:231. [PMID: 34187493 PMCID: PMC8243913 DOI: 10.1186/s12917-021-02934-6] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2021] [Accepted: 06/10/2021] [Indexed: 11/24/2022] Open
Abstract
Background Nucleosomes consist of DNA wrapped around a histone octamer core like thread on a spool to condense DNA as chromatin into chromosomes. Diseases such as cancer or inflammation lead to cell death, chromatin fragmentation and release of nucleosomes into the blood. The Nu.Q™ platform measures circulating nucleosomes in the blood of humans that result from disease and has been used to detect and identify cancer even at early stages. The objectives of this study are to quantify and better characterize nucleosomes in dogs with various stages of hemangiosarcoma (HSA) using this ELISA-based assay. Samples from 77 dogs with a confirmed diagnosis of hemangiosarcoma and 134 healthy controls were utilized for this study. The HSA samples were recruited from the Texas A&M University Small Animal Clinic (TAMU-SAC) or purchased from biobanks. All control samples were recruited from the TAMU-SAC. Results Dogs with hemangiosarcoma had a 6.6-fold increase in their median plasma nucleosome concentrations compared to controls (AUC 92.9 %). Elevated nucleosome concentrations were seen at all stages of disease and nucleosome concentrations increased with the stage of the disease. Conclusions Plasma nucleosome concentrations are a reliable way to differentiate dogs with hemangiosarcoma from healthy dogs. Further testing is underway to better characterize cancer associated HSA circulating nucleosomes and optimize future diagnostics for canine HSA detection. Supplementary Information The online version contains supplementary material available at 10.1186/s12917-021-02934-6.
Collapse
Affiliation(s)
- Heather Wilson-Robles
- College of Veterinary Medicine, Small Animal Clinical Sciences Department, Texas A&M University, College Station, TX, 77843, USA.
| | - Tasha Miller
- College of Veterinary Medicine, Small Animal Clinical Sciences Department, Texas A&M University, College Station, TX, 77843, USA
| | - Jill Jarvis
- College of Veterinary Medicine, Small Animal Clinical Sciences Department, Texas A&M University, College Station, TX, 77843, USA
| | - Jason Terrell
- Volition America & Volition Veterinary Diagnostic Development, 13215 Bee Cave Parkway, Galleria Oaks B, Suite 125, Austin, Texas, 78738, USA
| | - Theresa Kathleen Kelly
- College of Veterinary Medicine, Small Animal Clinical Sciences Department, Texas A&M University, College Station, TX, 77843, USA.,Volition America & Volition Veterinary Diagnostic Development, 13215 Bee Cave Parkway, Galleria Oaks B, Suite 125, Austin, Texas, 78738, USA
| | - Thomas Bygott
- Volition Diagnostics UK Ltd, 93-95 Gloucester Place, London, W1U 6JQ, UK
| | - Mhammed Bougoussa
- Belgian Volition SRL, 22 Rue Phocas Lejeune, Parc Scientifique Crealys, 5032, Isnes, Belgium
| |
Collapse
|
10
|
Foreman M, Vettorato E, Caine A, Monti P, Cherubini GB, Eminaga S. Serum C-reactive protein in dogs with paraplegia secondary to acute intervertebral disc extrusion. J Vet Intern Med 2021; 35:1857-1864. [PMID: 34085305 PMCID: PMC8295702 DOI: 10.1111/jvim.16179] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2020] [Revised: 05/05/2021] [Accepted: 05/14/2021] [Indexed: 01/08/2023] Open
Abstract
BACKGROUND Apart from the absence of nociception, there is no readily available prognostic test for dogs presenting with paraplegia secondary to acute intervertebral disc extrusion (IVDE). OBJECTIVE To assess if serum C-reactive protein (CRP) can predict the postoperative outcome in paraplegic dogs undergoing surgery for IVDE and to assess the association between serum CRP and presence/absence of nociception on admission, and serum CRP and presence/absence of intramedullary changes seen on magnetic resonance imaging (MRI). ANIMALS One hundred dogs that underwent surgery at our hospital between 2018 and 2020 because of acute paraplegia secondary to IVDE and in which serum CRP was measured. METHODS Retrospective observational cohort study. Dogs were classified as 4 or 5 according to the modified Frankel score (MFS) depending on presence/absence of nociception, respectively. MRI images were reviewed and the T2-weighted hyperintensity: L2 vertebral body length was measured. Postoperative outcome was defined as positive if nociception, ambulation or both returned after decompressive surgery. RESULTS The median (95% CI) serum CRP was 4 (4-5) and 6 (4-7) mg/L in MSF4 and MSF5, respectively (P = .03). A weak linear relationship (R2 = 0.049, P = .03) was found between CRP and the T2-weighted hyperintensity: L2 vertebral length. Outcome data was available for 85 dogs: CRP was 4 (4-5) and 5 (4-10) mg/L in positive and negative outcome dogs, respectively (P = .32). CONCLUSION AND CLINICAL IMPORTANCE Serum CRP did not predict outcome after surgery in dogs with paraplegia secondary to IVDE.
Collapse
Affiliation(s)
| | | | - Abby Caine
- Dick White Referrals, Cambs, United Kingdom
| | | | | | | |
Collapse
|
11
|
Chibuk J, Flory A, Kruglyak KM, Leibman N, Nahama A, Dharajiya N, van den Boom D, Jensen TJ, Friedman JS, Shen MR, Clemente-Vicario F, Chorny I, Tynan JA, Lytle KM, Holtvoigt LE, Murtaza M, Diaz LA, Tsui DWY, Grosu DS. Horizons in Veterinary Precision Oncology: Fundamentals of Cancer Genomics and Applications of Liquid Biopsy for the Detection, Characterization, and Management of Cancer in Dogs. Front Vet Sci 2021; 8:664718. [PMID: 33834049 PMCID: PMC8021921 DOI: 10.3389/fvets.2021.664718] [Citation(s) in RCA: 16] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2021] [Accepted: 02/23/2021] [Indexed: 12/14/2022] Open
Abstract
Cancer is the leading cause of death in dogs, in part because many cases are identified at an advanced stage when clinical signs have developed, and prognosis is poor. Increased understanding of cancer as a disease of the genome has led to the introduction of liquid biopsy testing, allowing for detection of genomic alterations in cell-free DNA fragments in blood to facilitate earlier detection, characterization, and management of cancer through non-invasive means. Recent discoveries in the areas of genomics and oncology have provided a deeper understanding of the molecular origins and evolution of cancer, and of the "one health" similarities between humans and dogs that underlie the field of comparative oncology. These discoveries, combined with technological advances in DNA profiling, are shifting the paradigm for cancer diagnosis toward earlier detection with the goal of improving outcomes. Liquid biopsy testing has already revolutionized the way cancer is managed in human medicine - and it is poised to make a similar impact in veterinary medicine. Multiple clinical use cases for liquid biopsy are emerging, including screening, aid in diagnosis, targeted treatment selection, treatment response monitoring, minimal residual disease detection, and recurrence monitoring. This review article highlights key scientific advances in genomics and their relevance for veterinary oncology, with the goal of providing a foundational introduction to this important topic for veterinarians. As these technologies migrate from human medicine into veterinary medicine, improved awareness and understanding will facilitate their rapid adoption, for the benefit of veterinary patients.
Collapse
Affiliation(s)
| | | | | | - Nicole Leibman
- The Cancer Institute, Animal Medical Center, New York, NY, United States
| | | | | | | | | | | | - M. Richard Shen
- RS Technology Ventures LLC., Rancho Santa Fe, CA, United States
| | | | | | | | | | | | - Muhammed Murtaza
- Department of Surgery and Center for Human Genomics and Precision Medicine, University of Wisconsin-Madison, Madison, WI, United States
| | - Luis A. Diaz
- Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, United States
| | | | | |
Collapse
|
12
|
Bitter EE, Townsend MH, Erickson R, Allen C, O'Neill KL. Thymidine kinase 1 through the ages: a comprehensive review. Cell Biosci 2020; 10:138. [PMID: 33292474 PMCID: PMC7694900 DOI: 10.1186/s13578-020-00493-1] [Citation(s) in RCA: 44] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/23/2020] [Accepted: 11/09/2020] [Indexed: 12/23/2022] Open
Abstract
Proliferation markers, such as proliferating cell nuclear antigen (PCNA), Ki-67, and thymidine kinase 1 (TK1), have potential as diagnostic tools and as prognostic factors in assessing cancer treatment and disease progression. TK1 is involved in cellular proliferation through the recovery of the nucleotide thymidine in the DNA salvage pathway. TK1 upregulation has been found to be an early event in cancer development. In addition, serum levels of TK1 have been shown to be tied to cancer stage, so that higher levels of TK1 indicate a more serious prognosis. As a result of these findings and others, TK1 is not only a potentially viable biomarker for cancer recurrence, treatment monitoring, and survival, but is potentially more advantageous than current biomarkers. Compared to other proliferation markers, TK1 levels during S phase more accurately determine the rate of DNA synthesis in actively dividing tumors. Several reviews of TK1 elaborate on various assays that have been developed to measure levels in the serum of cancer patients in clinical settings. In this review, we include a brief history of important TK1 discoveries and findings, a comprehensive overview of TK1 regulation at DNA to protein levels, and recent findings that indicate TK1’s potential role in cancer pathogenesis and its growing potential as a tumor biomarker and therapeutic target.
Collapse
Affiliation(s)
- Eliza E Bitter
- Department of Microbiology and Molecular Biology, Brigham Young University, 701 E University Pkwy, LSB room 4007, Provo, UT, 84602, USA.
| | - Michelle H Townsend
- Department of Microbiology and Molecular Biology, Brigham Young University, 701 E University Pkwy, LSB room 4007, Provo, UT, 84602, USA
| | - Rachel Erickson
- Department of Microbiology and Molecular Biology, Brigham Young University, 701 E University Pkwy, LSB room 4007, Provo, UT, 84602, USA
| | - Carolyn Allen
- Department of Microbiology and Molecular Biology, Brigham Young University, 701 E University Pkwy, LSB room 4007, Provo, UT, 84602, USA
| | - Kim L O'Neill
- Department of Microbiology and Molecular Biology, Brigham Young University, 701 E University Pkwy, LSB room 4007, Provo, UT, 84602, USA.
| |
Collapse
|
13
|
Yuki M, Shimada R, Omachi T. Primary Adenosquamous Cell Carcinoma of the Ileum in a Dog. Vet Sci 2020; 7:vetsci7040155. [PMID: 33066608 PMCID: PMC7712115 DOI: 10.3390/vetsci7040155] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2020] [Revised: 10/05/2020] [Accepted: 10/13/2020] [Indexed: 11/21/2022] Open
Abstract
A 9-year-old male, castrated Chihuahua was examined because of a 7-day history of intermittent vomiting. A mass in the small intestine was identified on abdominal radiography and ultrasonography. Laparotomy revealed a mass lesion originating in the ileum, and surgical resection was performed. The mass was histologically diagnosed as adenosquamous cell carcinoma. Chemotherapy with carboplatin was initiated, but the dog was suspected to have experienced recurrence 13 months after surgery and died 3 months later. To our knowledge, this is the first case report to describe the clinical course of adenosquamous cell carcinoma in the small intestine of a dog.
Collapse
Affiliation(s)
- Masashi Yuki
- Yuki Animal Hospital, 2-99 kiba-cho, Minato-ku, Nagoya, Aichi 455-0021, Japan;
- Correspondence:
| | - Roka Shimada
- Yuki Animal Hospital, 2-99 kiba-cho, Minato-ku, Nagoya, Aichi 455-0021, Japan;
| | - Tetsuo Omachi
- Patho Labo, 9-400 Oomurokougen, Ito, Shizuoka 413-0235, Japan;
| |
Collapse
|
14
|
Dobson JM. Significant advances in veterinary oncology - 60 years on. J Small Anim Pract 2019; 60:711-722. [PMID: 31742711 DOI: 10.1111/jsap.13076] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2018] [Revised: 07/26/2019] [Accepted: 07/31/2019] [Indexed: 01/10/2023]
Abstract
The first edition of the Journal of Small Animal Practice published in February 1960, contained a paper entitled "Recent Treatments of Malignant Neoplasia" by Dr Larry Owen. Now we have reached the 60th anniversary of JSAP, that article provides a baseline from which to review subsequent advances in veterinary oncology, which now includes worldwide networks that have resulted in veterinary oncology becoming the multidisciplinary speciality that it is today. There certainly have been many advances in understanding of the pathology and epidemiology of animal cancers and in methods of diagnosis and treatment. However, the subject has become so large and diverse that not all aspects can be covered in detail here. It should also be acknowledged that there are still many gaps in knowledge in this field and that, because of a lack of randomised clinical trials, the evidence base for what is often regarded as "standard of care" is weak.
Collapse
Affiliation(s)
- J M Dobson
- Department of Veterinary Medicine, University of Cambridge, Cambridge, CB3 0ES, UK
| |
Collapse
|
15
|
|
16
|
Ryu MO, Kim BG, Choi US, Baek KH, Song YK, Li Q, Seo KW, Ryeom S, Youn HY, Bhang DH. Extracellular cyclic adenosine monophosphate-dependent protein kinase A autoantibody and C-reactive protein as serum biomarkers for diagnosis of cancer in dogs. Vet Comp Oncol 2018; 17:99-106. [PMID: 30411459 PMCID: PMC6375080 DOI: 10.1111/vco.12450] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2018] [Revised: 10/03/2018] [Accepted: 10/03/2018] [Indexed: 11/28/2022]
Abstract
Protein kinase A, a cyclic adenosine monophosphate (AMP)‐dependent enzyme, normally exists within mammalian cells; however, in cancer cells, it can leak out and be found in the serum. Extracellular cyclic AMP‐dependent protein kinase A (ECPKA) has been determined to increase in the serum of cancer‐bearing dogs. However, there have been no reports in the veterinary literature on serum ECPKA autoantibody (ECPKA‐Ab) expression in dogs with cancer. The aim of this study was to evaluate ECPKA‐Ab and C‐reactive protein (CRP) as serum biomarkers for cancer in dogs. ECPKA‐Ab and CRP levels were detected by an enzyme‐linked immunosorbent assay in serum samples from dogs with malignant tumours (n = 167), benign tumours (n = 42), or non‐tumour disease (n = 155) and from healthy control dogs (n = 123). ECPKA‐Ab and CRP levels were significantly higher in the dogs with malignant tumours than in those with benign tumours or non‐tumour diseases, as well as in the healthy controls (P < 0.001, Kruskal‐Wallis test). There was a significant positive correlation between the neoplastic index, which was developed using ECPKA‐Ab and CRP levels, and the presence of cancer in dogs (P < 0.001); the area under the receiver‐operating characteristic curve was estimated to be >0.85 (P < 0.001). In conclusion, ECPKA‐Ab is a potential serum biomarker for a broad spectrum of cancers. Combined measurement of CRP and ECPKA‐Ab levels in serum improves the sensitivity and accuracy of a diagnosis of cancer in dogs.
Collapse
Affiliation(s)
- Min-Ok Ryu
- Laboratory of Veterinary Internal Medicine, College of Veterinary Medicine, Seoul National University, Seoul, Republic of Korea
| | - Byung-Gak Kim
- Department of Molecular and Cellular Biology, Sungkyunkwan University School of Medicine, Suwon, Republic of Korea
| | - Ul-Soo Choi
- Department of Veterinary Clinical Pathology and Bio-safety Research Institute, College of Veterinary Medicine, Chonbuk National University, Jeonju, Republic of Korea
| | - Kwan-Hyuck Baek
- Department of Molecular and Cellular Biology, Sungkyunkwan University School of Medicine, Suwon, Republic of Korea
| | | | - Qiang Li
- Laboratory of Veterinary Internal Medicine, College of Veterinary Medicine, Seoul National University, Seoul, Republic of Korea
| | - Kyoung-Won Seo
- College of Veterinary Medicine, Chungnam National University, Daejeon, Republic of Korea
| | - Sandra Ryeom
- Department of Cancer Biology, Perelman School of Medicine at the University of Pennsylvania, Pennsylvania
| | - Hwa-Young Youn
- Laboratory of Veterinary Internal Medicine, College of Veterinary Medicine, Seoul National University, Seoul, Republic of Korea
| | - Dong-Ha Bhang
- Department of Molecular and Cellular Biology, Sungkyunkwan University School of Medicine, Suwon, Republic of Korea.,BK21Plus Program for 21st Century Biomedical Science Leader Development, Sungkyunkwan University School of Medicine, Suwon, Republic of Korea
| |
Collapse
|
17
|
Bhang DH, Choi US, Kim BG, Lee SN, Lee S, Roh HS, Chung WJ, Jeon KO, Song WJ, Youn HY, Baek KH. Characteristics of extracellular cyclic AMP-dependent protein kinase as a biomarker of cancer in dogs. Vet Comp Oncol 2017; 15:1585-1589. [PMID: 28185388 DOI: 10.1111/vco.12304] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2016] [Revised: 12/20/2016] [Accepted: 12/20/2016] [Indexed: 11/30/2022]
Abstract
OBJECTIVE Early and proper diagnosis of cancer is the most critical factor for the survival and treatment of veterinary cancer patients. In this study, we evaluated extracellular cyclic AMP-dependent protein kinase A (ECPKA) level in serum as a useful cancer biomarker in dogs. METHODS ECPKA levels were detected in sera from dogs with cancers (n = 48), benign tumours (n = 18), and non-tumour diseases (n = 102) as well as healthy control dogs (n = 54) utilizing enzyme-linked immunosorbent assay (ELISA). RESULTS Sera from dogs bearing various types of cancer exhibited markedly increased levels of ECPKA by up to 7.1-, 8.8-, and 10.9-fold compared with those from dogs harbouring benign tumours, dogs with non-tumour diseases, and healthy control dogs, respectively (P < .0001). In addition, serum ECPKA level did not show statistically significant correlation with gender, breed, or age of dogs or their non-cancerous disease conditions. CONCLUSION Our data strongly propose that detection of serum ECPKA level is a potential and specific diagnostic tool for cancer in dogs.
Collapse
Affiliation(s)
- D H Bhang
- Department of Molecular and Cellular Biology, Samsung Biomedical Research Institute, Sungkyunkwan University School of Medicine, Suwon, Republic of Korea
| | - U S Choi
- Department of Veterinary Clinical Pathology and Bio-Safety Research Institute, College of Veterinary Medicine, Chonbuk National University, Jeonju, Republic of Korea
| | - B G Kim
- Department of Molecular and Cellular Biology, Samsung Biomedical Research Institute, Sungkyunkwan University School of Medicine, Suwon, Republic of Korea
| | - S-N Lee
- Department of Molecular and Cellular Biology, Samsung Biomedical Research Institute, Sungkyunkwan University School of Medicine, Suwon, Republic of Korea
| | - S Lee
- Department of Molecular and Cellular Biology, Samsung Biomedical Research Institute, Sungkyunkwan University School of Medicine, Suwon, Republic of Korea
| | - H-S Roh
- Department of Molecular and Cellular Biology, Samsung Biomedical Research Institute, Sungkyunkwan University School of Medicine, Suwon, Republic of Korea
| | - W-J Chung
- Ray Veterinary Medical Center, Seoul, Republic of Korea
| | - K O Jeon
- Department of Internal Veterinary Medicine, BK21 Plus Program for Veterinary Science, College of Veterinary Medicine, Seoul National University, Seoul, Republic of Korea
| | - W J Song
- Department of Internal Veterinary Medicine, BK21 Plus Program for Veterinary Science, College of Veterinary Medicine, Seoul National University, Seoul, Republic of Korea
| | - H-Y Youn
- Department of Internal Veterinary Medicine, BK21 Plus Program for Veterinary Science, College of Veterinary Medicine, Seoul National University, Seoul, Republic of Korea
| | - K-H Baek
- Department of Molecular and Cellular Biology, Samsung Biomedical Research Institute, Sungkyunkwan University School of Medicine, Suwon, Republic of Korea
| |
Collapse
|
18
|
Bryan JN. The Current State of Clinical Application of Serum Biomarkers for Canine Lymphoma. Front Vet Sci 2016; 3:87. [PMID: 27747218 PMCID: PMC5042957 DOI: 10.3389/fvets.2016.00087] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2016] [Accepted: 09/13/2016] [Indexed: 11/13/2022] Open
Abstract
Serum biomarkers of canine lymphoma activity for diagnosis, prognosis, and therapy monitoring have been of clinical interest for more than a decade. Tumor products, biochemical enzymes, cytokines, metabolic profiling, leakage enzymes, as well as serum proteins have been studied as biomarkers for lymphoma. Multiple biomarkers combined have been shown to be most sensitive and specific. C-reactive protein, thymidine kinase 1, and haptoglobin have been most extensively studied and commercialized in diagnostic tests, the TK Canine Cancer Panel and the Canine Lymphoma Blood Test. These tests have been evaluated either in cohorts of diseased and healthy dogs or in prospective studies of ill dogs, respectively, for application to clinical decision-making. Some evidence exists for application of these tests, but large-scale studies are lacking in a broad range of lymphoma forms. These biomarkers are commonly elevated at diagnosis and at relapse. Further study is necessary to determine if early intervention guided by biomarker elevation will improve quantity or quality of life for dogs with lymphoma.
Collapse
Affiliation(s)
- Jeffrey N Bryan
- Comparative Oncology Radiobiology and Epigenetics Laboratory, Department of Veterinary Medicine and Surgery, University of Missouri , Columbia, MO , USA
| |
Collapse
|